Failure Pattern and Factors Predictive of Local Failure in Rhabdomyosarcoma: A Report of Group III Patients on the Third Intergroup Rhabdomyosarcoma Study
- 15 May 2004
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (10) , 1902-1908
- https://doi.org/10.1200/jco.2004.08.124
Abstract
Purpose To analyze patterns of failure and factors predictive of local treatment failure in children enrolled on the third Intergroup Rhabdomyosarcoma Study who had either biopsy only or subtotal resection of their primary tumor, had no distant metastases, and received radiation therapy for local control. Patients and Methods Treatment failure was categorized as local, regional nodal, or distant metastatic. The 5-year cumulative risk of failure was estimated for each category and factors predictive of local failure risk were determined using the Cox model and binary recursive partitioning. Results The estimated 5-year cumulative incidence rates by failure category were: total local (with or without concurrent regional or distant failure), 19%; total regional nodal, 2%; total distant, 11%; and death from toxicity or unknown recurrence type, 4%. Lymph node involvement at diagnosis was the single factor most predictive of increased total local failure risk (5-year cumulative incidence 32%) compared with children with negative nodes or unknown node status (16%). No significant effect on local failure risk was observed by total radiotherapy dose over the prescribed range of 41.4 Gy to 50.4 Gy. For all patients (N = 405), the estimated 5-year failure-free survival and overall survival were, respectively, 70% and 78%. Conclusion Local failure after radiotherapy for group III rhabdomyosarcoma patients is the predominant type of relapse. Involved lymph nodes at diagnosis predict a higher risk of local and distant treatment failure compared with patients whose lymph nodes are negative.Keywords
This publication has 16 references indexed in Scilit:
- Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG 1 1For a complete list of the members of the Children’s Oncology Group Soft Tissue Sarcoma Committee (formerly Intergroup Rhabdomyosarcoma Group) representing the Children’s Oncology Group and the Quality Assurance Review Center, see the Appendix.International Journal of Radiation Oncology*Biology*Physics, 2001
- Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic DiseaseJournal of Clinical Oncology, 2001
- Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86Journal of Clinical Oncology, 1999
- Medulloblastoma: time–dose relationship based on a 30-year reviewInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84European Journal Of Cancer, 1998
- Radiation therapy for rhabdomyosarcoma: Local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study IIInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Local tumor control in rhabdomyosarcoma following low-dose irradiation: Comparison of group II and select group III patientsInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Local failure in childhood rhabdomyosarcoma and undifferentiated sarcoma: Prognostic factors and implications for curative therapyMedical and Pediatric Oncology, 1993
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958